Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Stock Is Rising Today

By Keith Speights - May 27, 2021 at 11:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company signed a key deal to market its hepatitis B vaccine in Germany.

What happened

Shares of Dynavax Technologies (DVAX 4.75%) were up by 3.6% as of 11:38 a.m. EDT on Thursday after having gained as much as 6.9% earlier in the session. The stock's rise came following the company's announcement that it has signed a deal with Bavarian Nordic to market and distribute its hepatitis B vaccine Heplisav B in Germany.

So what

Dynavax received market authorization for Heplisav B from the European Commission in February. However, that regulatory win was only the first step for the company in commercializing its hepatitis B vaccine throughout the European Union.

Gloved hands holding a syringe with a label stating "Hepatitis B" on it

Image source: Getty Images.

Bavarian Nordic has a solid marketing and distribution network already in place in Germany, so teaming up with it means that Dynavax won't have to build out its own sales force in the EU's largest market.

Now what

Dynavax expects to launch Heplisav B in Germany in the fourth quarter. However, the biotech company's stock could have other positive catalysts before then. Over the remainder of 2021, several of its collaboration partners are expected to report on the results from clinical studies of COVID-19 vaccine candidates that use Dynavax's CpG 1018 adjuvant.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$17.44 (4.75%) $0.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.